Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 11Recruiting 5Terminated 3Unknown 2Active not recruiting 2

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Breast Neoplasms 50Carcinoma, Non-Small-Cell Lung 36Ovarian Neoplasms 35Stomach Neoplasms 32Esophageal Neoplasms 29Uterine Cervical Neoplasms 21Esophageal Squamous Cell Carcinoma 19Fallopian Tube Neoplasms 16Lung Neoplasms 13Carcinoma, Ovarian Epithelial 13Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Squamous Cell 9Triple Negative Breast Neoplasms 8Recurrence 8Neoplasm Metastasis 6Endometrial Neoplasms 6Advanced Gastric Cancer 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Neoplasms 5Nasopharyngeal Neoplasms 5Hypopharyngeal Neoplasms 4Oropharyngeal Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Melanoma 3Laryngeal Neoplasms 3Carcinoma 3Anus Neoplasms 3Adenocarcinoma Of Esophagus 3

Interventions

Docetaxel 5Pemetrexed 4Capecitabine 4pembrolizumab 3Oxaliplatin 3icotinib 2Radiation 2Paclitaxel 2Gemcitabine 2Gefitinib 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Carboplatin 2sintilimab 1rucaparib 1regorafenib 1olaparib 1lenvatinib 1iron isomaltoside 1000 1ipatasertib 1iopromide 1gluconic acid 1elemene 1capecitabine-irinotecan combination 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma × Paclitaxel × Clear all
NCT02509286 2024-05-08

ESOPEC

University Hospital Schleswig-Holstein

Phase 3 Unknown
438 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡